MariMedMRMD -3.57% OCF Yield % is 26.23 as of Jun. 27, 2026, which is 861% above its 10-year median of 2.73. The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, MariMed ranks better than 95.02% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
MariMed OCF Yield % Related Terms
MariMed OCF Yield % Historical Data
* Premium members only.
The historical data trend for MariMed's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MariMed OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MariMed's OCF Yield % distribution charts can be found below:
* The bar in red indicates where MariMed's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MariMed (MRMD) has a OCF Yield % of 26.23 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on MariMed and its competitors. This is 861% above median its historical median of 2.73. According to the industry distribution chart, MariMed ranks #50 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 5%.
Is MariMed's OCF Yield % too high?
MariMed's current OCF Yield % of 26.23 is 861% above median its 10-year median of 2.73. The Drug Manufacturers industry median OCF Yield % is 3.61. MariMed's value of 26.23 is 626.6% above this industry median. Based on the distribution chart, MariMed ranks #50 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does MariMed's OCF Yield % compare to CPHI and RMTI?
According to the Drug Manufacturers industry distribution chart, MariMed ranks #50 out of 1005 companies for OCF Yield %. This places MariMed in the top 5% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 3.61. MariMed's value of 26.23 is 626.6% above this benchmark. While the company's 10-year median is 2.73 vs. the industry median of 3.61, MariMed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.61, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MariMed's current OCF Yield % of 26.23 is 626.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on MariMed and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MariMed's current OCF Yield % is 26.23, which is 861% above median its own 10-year median of 2.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MariMed stock overvalued right now?
Based on GuruFocus' analysis, MariMed (MRMD) is currently considered Possible Value Trap. The stock's GF Value™ is $0.16, compared to a current price of $0.07 — trading 56.1% below its estimated fair value. The current OCF Yield % is 26.23, which is 861% above median its 10-year median of 2.73 and 626.6% above the Drug Manufacturers industry median of 3.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For MariMed (MRMD), the current OCF Yield % is 26.23 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MariMed Inc is a multi-state cannabis operator in the United States dedicated to improving lives every day through its high-quality products. The company develops, owns, and manages seed to sale state-licensed, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. It has created and continues to develop its own brands of cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other top cannabis products, in select domestic markets. Its operations are conducted in compliance with applicable state and local laws and regulations in the jurisdictions in which it operates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRMD has been successfully added to your 